CoChat

Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial

Open access
González, Raquel, Mombo-Ngoma, Ghyslain, Ouédraogo, Smaïla, Kakolwa, Mwaka A., Abdulla, Salim, Accrombessi, Manfred, Aponte, John J., Akerey-Diop, Daisy, Basra, Arti, Briand, Valérie, Capan, Meskure, Cot, Michel, Kabanywanyi, Abdunoor M., Kleine, Christian, Kremsner, Peter G., Macete, Eusebio, Mackanga, Jean-Rodolphe, Massougbodgi, Achille, Mayor, Alfredo, Nhacolo, Arsenio, Pahlavan, Golbahar, Ramharter, Michael, Rupérez, María, Sevene, Esperança, Vala, Anifa, Zoleko-Manego, Rella, Menéndez, Clara · 2014 · PLoS Medicine
Cited by 136

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended by WHO to prevent malaria in African pregnant women. The spread of SP parasite resistance has raised concerns regarding long-term use for IPT. Mefloquine (MQ) is the most promising of available alternatives to SP based on safety profile, long half-life, and high efficacy in Africa. We evaluated the safety and efficacy of MQ for IPTp compared to those of SP in HIV-negative women. METHODS AND FINDINGS: A total of 4,749 pregnant women were enrolled in an open-label randomized clinical trial conducted in Benin, Gabon, Mozambique, and Tanzania comparing two-dose MQ or SP for IPTp and MQ tolerability of two different regimens. The study arms were: (1) SP, (2) single dose MQ (15 mg/kg), and (3) split-dose MQ in the context of long lasting insecticide treated nets. There was no difference on low birth weight prevalence (primary study outcome) between groups (360/2,778 [13.0%]) for MQ group and 177/1,398 (12.7%) for SP group; risk ratio [RR], 1.02 (95% CI 0.86-1.22; p=0.80 in the ITT analysis). Women receiving MQ had reduced risks of parasitemia (63/1,372 [4.6%] in the SP group and 88/2,737 [3.2%] in the MQ group; RR, 0.70 [95% CI 0.51-0.96]; p=0.03) and anemia at delivery (609/1,380 [44.1%] in the SP group and 1,110/2743 [40.5%] in the MQ group; RR, 0.92 [95% CI 0.85-0.99]; p=0.03), and reduced incidence of clinical malaria (96/551.8 malaria episodes person/year [PYAR] in the SP group and 130/1,103.2 episodes PYAR in the MQ group; RR, 0.67 [95% CI 0.52-0.88]; p=0.004) and all-cause outpatient attendances during pregnancy (850/557.8 outpatients visits PYAR in the SP group and 1,480/1,110.1 visits PYAR in the MQ group; RR, 0.86 [0.78-0.95]; p=0.003). There were no differences in the prevalence of placental infection and adverse pregnancy outcomes between groups. Tolerability was poorer in the two MQ groups compared to SP. The most frequently reported related adverse events were dizziness (ranging from 33.9% to 35.5% after dose 1; and 16.0% to 20.8% after dose 2) and vomiting (30.2% to 31.7%, after dose 1 and 15.3% to 17.4% after dose 2) with similar proportions in the full and split MQ arms. The open-label design is a limitation of the study that affects mainly the safety assessment. CONCLUSIONS: Women taking MQ IPTp (15 mg/kg) in the context of long lasting insecticide treated nets had similar prevalence rates of low birth weight as those taking SP IPTp. MQ recipients had less clinical malaria than SP recipients, and the pregnancy outcomes and safety profile were similar. MQ had poorer tolerability even when splitting the dose over two days. These results do not support a change in the current IPTp policy. TRIAL REGISTRATION: ClinicalTrials.gov NCT 00811421; Pan African Clinical Trials Registry PACTR 2010020001429343 Please see later in the article for the Editors' Summary.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001733

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 136

Metadata

Authors
González, R., Mombo-Ngoma, G., Ouédraogo, S., Kakolwa, M. A., Abdulla, S., Accrombessi, M., Aponte, J. J., Akerey-Diop, D., Basra, A., Briand, V., Capan, M., Cot, M., Kabanywanyi, A. M., Kleine, C., Kremsner, P. G., Macete, E., Mackanga, J.-R., Massougbodgi, A., Mayor, A., Nhacolo, A., Pahlavan, G., Ramharter, M., Rupérez, M., Sevene, E., Vala, A., Zoleko-Manego, R., & Menéndez, C.
Venue
PLoS Medicine
Published
2014-09-23
Volume
11
Issue
9
Pages
e1001733
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2129955913
Cited by
136
References
12
FWCI
17.16
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1001733
The paper
González, R., Mombo-Ngoma, G., Ouédraogo, S., Kakolwa, M. A., Abdulla, S., Accrombessi, M., Aponte, J. J., Akerey-Diop, D., Basra, A., Briand, V., Capan, M., Cot, M., Kabanywanyi, A. M., Kleine, C., Kremsner, P. G., Macete, E., Mackanga, J.-R., Massougbodgi, A., Mayor, A., . . . Menéndez, C. (2014). Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001733

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.